BR0013276A - Pharmaceutical formulation for parenteral use comprising estramustine phosphate as active ingredient - Google Patents

Pharmaceutical formulation for parenteral use comprising estramustine phosphate as active ingredient

Info

Publication number
BR0013276A
BR0013276A BR0013276-4A BR0013276A BR0013276A BR 0013276 A BR0013276 A BR 0013276A BR 0013276 A BR0013276 A BR 0013276A BR 0013276 A BR0013276 A BR 0013276A
Authority
BR
Brazil
Prior art keywords
active ingredient
pharmaceutical formulation
parenteral use
estramustine phosphate
phosphate
Prior art date
Application number
BR0013276-4A
Other languages
Portuguese (pt)
Inventor
Lorena Muggetti
Paolo Colombo
Alessandro Martini
Giovanni Buzzi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9918779.1A external-priority patent/GB9918779D0/en
Priority claimed from IT99MI001998 external-priority patent/IT1313629B1/en
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0013276A publication Critical patent/BR0013276A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçãO FARMACêUTICA PARA USO PARENTERAL QUE COMPREENDE FOSFATO DE ESTRAMUSTINA, COM INGREDIENTE ATIVO". Onde a proporção em peso é conforme descrita no relatório descritivo, útil na terapia antitumor, para ser administrada de acordo com um regime quimioterapêutico associado com um ou mais agentes quimioterapêuticos. Tal formulação possibilita a administração de fosfato de estramustina ausente de efeitos colaterais no local da injeção."PHARMACEUTICAL FORMULATION FOR PARENTERAL USE UNDERSTANDING STRAMUSTINE PHOSPHATE, WITH ACTIVE INGREDIENT". Where the weight ratio is as described in the descriptive report useful in antitumor therapy to be administered according to a chemotherapeutic regimen associated with one or more chemotherapeutic agents. Such a formulation makes it possible to administer estramustine phosphate without side effects at the injection site.

BR0013276-4A 1999-08-09 2000-08-03 Pharmaceutical formulation for parenteral use comprising estramustine phosphate as active ingredient BR0013276A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9918779.1A GB9918779D0 (en) 1999-08-09 1999-08-09 Formulations for parenteral use of estramustine phosphate and albumin
IT99MI001998 IT1313629B1 (en) 1999-09-27 1999-09-27 New pharmaceutical compositions comprising estramustine phosphate and human albumin, useful for treating cancer e.g. prostate, breast, lung, pancreatic, colorectal, ovarian or brain cancer or melanoma
PCT/EP2000/007678 WO2001010446A2 (en) 1999-08-09 2000-08-03 Formulations for parenteral use of estramustine phosphate and albumin

Publications (1)

Publication Number Publication Date
BR0013276A true BR0013276A (en) 2004-08-03

Family

ID=26315835

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013276-4A BR0013276A (en) 1999-08-09 2000-08-03 Pharmaceutical formulation for parenteral use comprising estramustine phosphate as active ingredient

Country Status (17)

Country Link
EP (1) EP1206266A2 (en)
JP (1) JP2003506408A (en)
KR (1) KR20020019967A (en)
CN (1) CN1511037A (en)
AU (1) AU6280900A (en)
BR (1) BR0013276A (en)
CA (1) CA2380312A1 (en)
CZ (1) CZ2002376A3 (en)
EA (1) EA200200234A1 (en)
HU (1) HUP0202645A3 (en)
IL (1) IL147745A0 (en)
MX (1) MXPA02001395A (en)
NO (1) NO20020631D0 (en)
NZ (1) NZ517632A (en)
PL (1) PL353406A1 (en)
SK (1) SK1782002A3 (en)
WO (1) WO2001010446A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100426450B1 (en) * 2002-03-16 2004-04-13 박래옥 Anticancer Composition Comprising Citric acid, Albumin And Zinc
SI1585548T1 (en) * 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
KR101198346B1 (en) 2003-04-08 2012-11-06 노보 노르디스크 에이/에스 Regeneration of chromatographic stationary phases
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
DE102006024528A1 (en) * 2006-05-23 2007-11-29 Albupharm Heidelberg Gmbh & Co. Kg New formulation of a cytostatic, especially cis-platin, oriented on tumor physiology

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59108800A (en) * 1982-12-13 1984-06-23 Japan Atom Energy Res Inst Fine particle having guided missile action and slow-releasing function of carcinostatic agent
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
EP1206266A2 (en) 2002-05-22
WO2001010446A3 (en) 2001-05-25
MXPA02001395A (en) 2002-08-12
HUP0202645A3 (en) 2004-06-28
WO2001010446A2 (en) 2001-02-15
SK1782002A3 (en) 2002-05-09
IL147745A0 (en) 2002-08-14
PL353406A1 (en) 2003-11-17
NO20020631L (en) 2002-02-08
AU6280900A (en) 2001-03-05
HUP0202645A2 (en) 2002-12-28
NO20020631D0 (en) 2002-02-08
JP2003506408A (en) 2003-02-18
CN1511037A (en) 2004-07-07
EA200200234A1 (en) 2002-06-27
NZ517632A (en) 2004-02-27
CA2380312A1 (en) 2001-02-15
KR20020019967A (en) 2002-03-13
CZ2002376A3 (en) 2002-06-12

Similar Documents

Publication Publication Date Title
FI863664A0 (en) EMULSIONSKOMPOSITIONER FOER DOSERING AV I VATTEN SVAORLOESLIGA JONISERBARA HYDROFOBA LAEKEMEDEL.
DE69226369D1 (en) System with increased skin penetration for improved topical administration of drugs
AR025959A1 (en) DERIVATIVES OF TER.-BUTIL- (7-METHYL-IMIDAZO [1,2, a] PIRIDIN-3-IL) -AMINA, PROCEDURE FOR THEIR PREPARATION, DRUGS THAT CONTAIN THEM, THEIR USE FOR THE PREPARATION OF A MEDICATION FOR THE INHIBITION OF NON-SYNTHEASE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
BRPI0513673A (en) method for increasing the efficacy and transport of enterally administered biologically active compounds, a vehicle used for enteral administration of biologically active compounds, a pharmaceutical composition and the use of an effective amount of one or more phosphate derivatives
KR920007629A (en) A pharmaceutical composition exhibiting activity in the treatment of neurological diseases of AIDS patients by containing at least one compound selected from SALMe salt, 5-MTHF and 5-FTHF as an active ingredient.
KR880004808A (en) Pharmaceutical Compositions Having Antineoplastic Activity
DE69322251D1 (en) MEDICAL COMPOSITION
DE3669106D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING FLAVANOLIGNANES AND PHOSPHOLIPIDES AS ACTIVE INGREDIENTS.
BR0211198A (en) Pharmaceutical compositions and their use
ATE216246T1 (en) PHARMACEUTICAL PREPARATION BASED ON A DICLOFENAC SALT AND THE COMPOUND THIOCOLCHICOSIDE
BR0013276A (en) Pharmaceutical formulation for parenteral use comprising estramustine phosphate as active ingredient
BR0014071A (en) Formulations for parenteral use of estramustine phosphate and amino acids
KR920019350A (en) Pharmaceutical Compositions for Autoimmune Disease Therapy
BR0014062A (en) Formulations for parenteral use of estramustine phosphate and sulfoalkylether cyclodextrins
NZ501987A (en) Single, high dosage intravenous administration of estramustine phosphate
AR029415A1 (en) PIRROLES REPLACED, A PROCEDURE FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION, AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES
Lorenzetti et al. Anti-inflammatory effects of BN-52021
Martins et al. Anesthesia prevents PAF-acether-induced leukocytosis in rats, but hemoconcentration is maintained
CO4980890A1 (en) AN ANTIMALARIC COMPOSITION METHOD FOR TREATING MALARIA
Cheng Benefits of combination therapy confirmed
BR0113844A (en) Use of arginine in the preparation of a drug to prevent and treat side effects associated with intravenous drug administration.
Whitfield HIV antiviral drug guide 1998
Lokich et al. Pilot study of ambulatory infusional ifosfamide admixed with carboplatin
Gilden Three drugs now in expanded access
HN1997000048A (en) 1,3 - OXATIOLANOS SUBSTITUTED WITH ANTIVIRIC PROPERTIES.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.